This prospective study compares an oral direct factor Xa inhibitor with LMWH for thromboprophylaxis in the patients undergoing THA.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
639
Rivaroxaban was taken orally in a dosage of 10mg once daily
Enoxaparin was injected subcutaneously in a dosage of 40mg once daily
subcutaneous injection of 1 cc of normal saline once daily
Major wound complication
hematoma : size, site woozing : frequency, amount, dressing change count infection : culture
Time frame: 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.